GU Oncology Now

11/11/2023

The results of the SELECT trial show that people who are overweight or obese but do not have diabetes taking semaglutide for more than 3 years had a 20% risk reduction of heart attack, stroke, or death due to cardiovascular disease (CVD) and lost over 9% of body weight. The results were presented in a late-breaking science presentation today at the American Heart Association's Scientific Sessions 2023, taking place Nov. 11-13, in Philadelphia, PA, and simultaneously published today in The New England Journal of Medicine.

Read More:

Semaglutide reduced major CVD risk by 20% in adults with overweight or obesity, but not diabetes.

16/03/2023

Frequent efforts to turn tyrosine kinase inhibitors and immune-checkpoint inhibitors into adjuvant treatments have occurred over the past decade, as they have had the most beneficial treatment outcomes for . Read more:

A team of researchers reviewed existing literature on adjuvant therapy for renal cell carcinoma (RCC) and provided a summary of patient characteristics that may result in the most favorable responses to treatment.

15/03/2023

A team of researchers from the Roswell Park Comprehensive Cancer Center in Buffalo, New York, set out to determine the preferred sequence of perioperative systemic therapy for node-positive . Read more:

Adjuvant chemotherapy (AC) is considered a standard-of-care treatment for high-risk upper tract urothelial carcinoma (UTUC) based on results from the POUT trial, which examined perioperative chemotherapy versus surveillance for UTUC. AC was found to have superior disease-free survival when compared....

09/03/2023

The Uromigos were joined by Daniel George, MD, to review presentations from ASCO , including triplet versus doublet therapy, the ARASENS trial, and the ZIRCON phase 3 trial. Listen here:

The Uromigos are joined by Daniel George, MD, to review presentations from the 2023 ASCO GU Cancers Symposium, including triplet versus doublet therapy, the ARASENS trial, and the ZIRCON phase 3 trial. Dr. George is a medical oncologist at Duke Health, specializing in genitourinary malignancies.

08/03/2023

A recent study determined the surgical efficacy of RPLND and evaluated recurrence after primary RPLND for CS IIA/IIB to determine if certain clinical factors could predict disease recurrences. Learn more:

Clinical stage (CS) II seminoma is commonly treated with radiotherapy or chemotherapy based on guidelines from the National Comprehensive Cancer Network. Primary retroperitoneal lymph node dissection (RPLND) has recently demonstrated success as another first-line therapy option for retroperitoneal (...

07/03/2023

The Michigan Urological Surgery Improvement Collaborative (MUSIC) experience evaluated the 5-year treatment-free survival for patients with favorable intermediate-risk , and recently published their exciting data. Learn more:

It is increasingly common for patients with favorable intermediate-risk prostate cancer to be managed with active surveillance, but more information is needed to analyze short- and long-term outcomes.

06/03/2023

We spoke with Rachelle Rodriguez, MS, APRN, AOCNP, the GU advanced practice provider supervisor at Moffitt Cancer Center, on her role in helping Moffitt grow its APP presence as well as the specific challenges for APPs in their treatment of GU patients. Read more:

In January 2023, Rachelle Rodriguez, MS, APRN, AOCNP, the genitourinary (GU) advanced practice provider (APP) supervisor at Moffitt Cancer Center, was honored by Moffitt with the Award of Excellence in Innovations in Clinical Care.

03/03/2023

A recent phase 3 clinical trial demonstrated that intravesical interferon-alpha gene therapy combined with nadofaragene firadenovec is a clinically effective treatment combination for patients with non-muscle-invasive . Read more:

A recent phase 3 clinical trial demonstrated that intravesical interferon-alpha (IFNα) gene therapy plus nadofaragene firadenovec is a clinically effective treatment combination for patients with non-muscle-invasive bladder cancer (NMIBC), providing a potential new therapeutic approach for a diseas...

01/03/2023

How does cost of care impact patient decision-making for localized treatment? GU Oncology Now contributor Akhil A Saji highlights the research available on costs related to the treatment of localized prostate cancer—and the associated outcomes—in the US. Read more:

The National Cancer Institute estimates nearly 270,000 new cases of prostate cancer will be diagnosed in the United States in 2023, and approximately 14% to 15% of patients with prostate cancer will also be diagnosed with advanced-stage disease.1,2

28/02/2023

Howard Korman, MD, and Savitha Balaraman, MD, describe the importance of genetic testing for patients newly diagnosed with , opine on whether genetic testing is underutilized, and offer strategies to improve testing rates in our latest interview. Watch here:

Howard Korman, MD, Comprehensive Urology and Wayne State University; and Savitha Balaraman, MD, Comprehensive Urology, Oakland Medical Group Hematology Oncology, Michigan Health Care Professionals, and Oakland University William Beaumont School of Medicine, describe the importance of genetic testing...

27/02/2023

GU Oncology Now contributor Akhil A Saji details the ongoing QUILT-3.032 trial that is investigating the use of an IL-15 superagonist for the treatment of NMIBC in BCG-unresponsive patients. Read more: https://buff.ly/3EGJ7EL